



# Johnson & Johnson (JNJ)

Updated July 19<sup>th</sup>, 2022 by Nathan Parsh

## Key Metrics

<b>Current Price:</b>	\$172	<b>5 Year CAGR Estimate:</b>	8.2%	<b>Market Cap:</b>	\$458 billion
<b>Fair Value Price:</b>	\$171	<b>5 Year Growth Estimate:</b>	6.0%	<b>Ex-Dividend Date:</b>	08/23/22 <sup>1</sup>
<b>% Fair Value:</b>	101%	<b>5 Year Valuation Multiple Estimate:</b>	-0.1%	<b>Dividend Payment Date:</b>	09/07/22 <sup>2</sup>
<b>Dividend Yield:</b>	2.6%	<b>5 Year Price Target</b>	\$229	<b>Years Of Dividend Growth:</b>	60
<b>Dividend Risk Score:</b>	A	<b>Retirement Suitability Score:</b>	A	<b>Rating:</b>	Hold

## Overview & Current Events

Johnson & Johnson is a diversified health care company and a leader in the area of pharmaceuticals (~49% of sales), medical devices (~34% of sales) and consumer products (~17% of sales). Johnson & Johnson was founded in 1886 and employs more than 141,000 people around the world. The company has annual sales in excess of \$98 billion.

On November 12<sup>th</sup>, 2021, Johnson & Johnson announced plans to spin off its consumer health business into a standalone company. The transaction is expected to be completed within 18 to 24 months of the announcement. The company has had separation costs of \$370 million for the first half of 2022.

On July 19<sup>th</sup>, 2022, Johnson & Johnson released second quarter earnings results for the period ending June 30<sup>th</sup>, 2022. Revenue grew 3% to \$24 billion and was \$180 million ahead of estimates. Adjusted earnings-per-share of \$2.59 compared favorably to \$2.48 in the prior year and was \$0.04 better than expected.

Pharmaceutical revenues increased 6.7%, led by a 14% improvement in Oncology. *Darzalex*, which treats multiple myeloma, once again had market share gains in all regions. *Imbruvica*, which treats lymphoma, led in market share, but had declines due to competitive pressures. Immunology was up 4.3%, again due to higher demand for *Stelara*, which treats immune-mediated inflammatory diseases, in the areas of Crohn's Disease and Ulcerative Colitis. Infectious Diseases continues to perform well, as revenue was up 29%. This was again mostly due to the company's Covid-19 vaccine. Consumer revenue declined 1.3% as gains in Over-the-Counter and Women's Health only partially offset weakness in Skin Health & Beauty, Oral Care, and Wound Care. MedTech was down 1.1% for the quarter. Strength in Vision and Interventional Solutions was more than offset by weakness in Surgery and Orthopaedics.

Johnson & Johnson offered revised guidance for the year as well. The company now expects adjusted earnings-per-share of \$10.00 to \$10.10 for 2022, down from \$10.15 to \$10.30 and \$10.40 to \$10.60 previously, and revenue of \$93.3 billion to \$94.3 billion, down from \$97.3 billion to \$98.3 billion and \$98.9 billion to \$100.4 billion. Leadership stated that revised guidance was due to a strengthening U.S. dollar. Johnson & Johnson is also suspending its Covid-19 vaccine sales guidance due to a global supply surplus.

## Growth on a Per-Share Basis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
<b>EPS</b>	\$5.10	\$5.52	\$5.70	\$5.48	\$5.93	\$7.30	\$8.18	\$8.68	\$8.03	\$9.80	<b>\$10.05</b>	<b>\$13.45</b>
<b>DPS</b>	\$2.40	\$2.59	\$2.76	\$2.95	\$3.15	\$3.32	\$3.54	\$3.80	\$4.04	\$4.19	<b>\$4.52</b>	<b>\$6.05</b>
<b>Shares<sup>3</sup></b>	2779	2821	2783	2755	2707	2683	2650	2684	2669	2670	<b>2668</b>	<b>2600</b>

Johnson & Johnson has grown earnings over the past 10 years at a rate of 7.5%. The company managed to grow earnings before, during and after the last recession, showing that the company's products are in demand regardless of market conditions. We expect earnings-per-share to grow at a rate of 6% per year through 2027 due to gains in revenue and

<sup>1</sup> Estimated ex-dividend date.

<sup>2</sup> Estimated dividend payment date.

<sup>3</sup> In millions of shares.

Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated July 19<sup>th</sup>, 2022 by Nathan Parsh

share repurchases. This is consistent with Johnson & Johnson's earnings growth composition in the past, however, most growth will come from revenue expansion as the buyback is good for a low-single-digit gain annually.

On April 19<sup>th</sup>, 2022, Johnson & Johnson announced a 6.6% dividend increase for the June 7<sup>th</sup>, 2022 payment date, giving the company 60 consecutive years of dividend growth.

## Valuation Analysis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Now	2027
Avg. P/E	13.1	15.6	17.7	18.2	19.1	23.9	23.7	15.6	18.2	17.5	17.1	17.0
Avg. Yld.	3.6%	3.0%	2.7%	3.0%	2.8%	2.6%	2.7%	2.8%	2.7%	2.4%	2.6%	2.6%

Shares of Johnson & Johnson have declined \$11, or 6.0%, since our April 19<sup>th</sup>, 2022 update. Using the current share price and revised guidance for earnings-per-share for the year, Johnson & Johnson trades with a price-to-earnings ratio of 17.1, which is very close to our target price-to-earnings ratio of 17. At this point, valuation doesn't appear to play much of a factor in total returns.

## Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
Payout	47%	47%	48%	54%	53%	46%	43%	44%	50%	43%	45%	45%

Johnson & Johnson has a reasonably low dividend payout ratio. This gives the company ample room to raise its dividend, even in a prolonged recession. One of Johnson & Johnson's key competitive advantages is the size and scale of its business. The company is a worldwide leader in a number of healthcare categories. Johnson & Johnson's diversification allows it to continue to grow even if one of the segments is underperforming. This can be seen in the last quarterly report where declines in Consumer were offset by gains in Medical Devices and Pharmaceuticals.

## Final Thoughts & Recommendation

Following second quarter earnings results, Johnson & Johnson is expected to offer a total annual return of 8.2% through 2027, up from our prior forecast of 7.3%. Our projected return stems from a 6% earnings growth rate and a starting yield of 2.6%, offset by a small headwind from multiple contraction. Johnson & Johnson performed well during the quarter, but downwardly revised its guidance for the remainder of the year. The company did see good results in its Pharmaceutical business, but the others were lower for the quarter. Johnson & Johnson remains on track to divest its Consumer business to focus on the faster growing Pharmaceutical and MedTech segments. We have lowered our 2027 price target \$4 to \$229 due to revised guidance and continue to rate shares of Johnson & Johnson as a hold due to projected returns.

## Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated July 19<sup>th</sup>, 2022 by Nathan Parsh

## Income Statement Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
<b>Revenue</b>	71312	74331	70074	71890	76450	81581	82059	82584	82584	93775
<b>Gross Profit</b>	48970	51585	48538	50101	51011	54490	54503	54157	54157	63920
<b>Gross Margin</b>	68.7%	69.4%	69.3%	69.7%	66.7%	66.8%	66.4%	65.6%	65.6%	68.2%
<b>SG&amp;A Exp.</b>	21830	21954	21203	20067	21520	22540	22178	22084	22084	24659
<b>D&amp;A Exp.</b>	4104	3895	3746	3754	5642	6929	7009	7231	7231	7390
<b>Operating Profit</b>	18957	21137	18289	20891	18897	21175	20970	19914	19914	24547
<b>Op. Margin</b>	26.6%	28.4%	26.1%	29.1%	24.7%	26.0%	25.6%	24.1%	24.1%	26.2%
<b>Net Profit</b>	13831	16323	15409	16540	1300	15297	15119	14714	14714	20878
<b>Net Margin</b>	19.4%	22.0%	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	17.8%	22.3%
<b>Free Cash Flow</b>	13819	14996	16106	15541	17777	18531	19918	20189	20189	19758
<b>Income Tax</b>	1640	4240	3787	3263	16373	2702	2209	1783	1783	1898

## Balance Sheet Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
<b>Total Assets</b>	121347	132683	130358	133411	141208	157303	152954	157728	174894	182018
<b>Cash &amp; Equivalents</b>	14911	20927	14523	13732	18972	17824	18107	17305	13985	14487
<b>Acc. Receivable</b>	11309	11713	10985	10734	11699	13490	14098	14481	13576	15283
<b>Inventories</b>	7495	7878	8184	8053	8144	8765	8599	9020	9344	10387
<b>Goodwill &amp; Int.</b>	51176	50745	49054	47393	49681	85134	78064	81282	89795	81638
<b>Total Liabilities</b>	56521	58630	60606	62261	70790	97143	93202	98257	111616	107995
<b>Accounts Payable</b>	5831	6266	7633	6668	6918	7310	7537	8544	9505	11055
<b>Long-Term Debt</b>	16165	18180	18760	19861	27126	34581	30480	27696	35266	33751
<b>Total Equity</b>	64826	74053	69752	71150	70418	60160	59752	59471	63278	74023
<b>LTD/E Ratio</b>	0.25	0.25	0.27	0.28	0.39	0.57	0.51	0.47	0.56	0.46

## Profitability & Per Share Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
<b>Return on Assets</b>	9.2%	10.9%	12.4%	11.7%	12.0%	0.9%	9.9%	9.7%	8.8%	11.7%
<b>Return on Equity</b>	17.8%	19.9%	22.7%	21.9%	23.4%	2.0%	25.5%	25.4%	24.0%	30.4%
<b>ROIC</b>	13.8%	16.0%	18.1%	17.2%	17.5%	1.4%	16.5%	17.0%	15.8%	20.2%
<b>Shares Out.</b>	2779	2821	2783	2755	2707	2683	2650	2684	2669	2667
<b>Revenue/Share</b>	23.90	24.79	25.95	24.91	25.78	27.85	29.90	30.57	30.92	35.07
<b>FCF/Share</b>	4.43	4.80	5.24	5.73	5.57	6.48	6.79	7.42	7.56	7.39

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.